Drug intelligence / Profile preview

Gastrinal HD

Development stage: Unknown
Lead developer: MEPROFARM
Modality: Small Molecules
Administration: Oral

Overview

Gastrinal HD is an over-the-counter antacid and antiflatulent combination medication developed and manufactured by PT. Meprofarm Pharmaceutical Industries. It is primarily used to alleviate symptoms associated with gastric hyperacidity, such as heartburn, bloating, and indigestion, as well as conditions like gastritis and peptic ulcers. The formulation typically contains hydrotalcite (a magnesium-aluminum carbonate hydrate), magnesium hydroxide, and simethicone. Hydrotalcite and magnesium hydroxide act as antacids by neutralizing gastric acid, thereby increasing the pH of the stomach contents. Simethicone acts as an antiflatulent by reducing the surface tension of gas bubbles in the digestive tract, allowing them to be more easily expelled.

Brand names: Gastrinal HD

Beyond the preview

Go deeper on Gastrinal HD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrinal HD.

Explore the full profile